JNJ · News · 20260910N

Product Launch and Transition

JOHNSON & JOHNSON · 2026-09-10 · Importance 34 · Surprise 42

Johnson & Johnson received CE Marking for the ACUVUE OASYS MAX 2-Week reusable contact lens in Europe. The lens uses proprietary MAX technologies, including OptiBlue Light Filter and TearStable Technology, and expands the existing ACUVUE OASYS MAX portfolio. The product is expected to launch in select European markets in late 2026 and has not yet received FDA approval for U.S. sale.

Key facts

• Ancora Advisors LLC lowered its stake in Johnson & Johnson by 8.5% during the undefined quarter. source
• ACUVUE OASYS MAX 2-Week contact lens features proprietary MAX technologies. source
• After selling 21,326 shares, Ancora Advisors LLC owned 229,968 shares of Johnson & Johnson. source
• The broader pharmaceuticals industry average P/E ratio cited is 16.2x. source
• Discounted Cash Flow model suggests Johnson & Johnson is undervalued by 26.7% based on projected future cash flows. source
• Johnson & Johnson's P/E ratio is 30.6x. source